Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
Whitehawk Therapeutics (Nasdaq: WHWK) said Dave Lennon, PhD, President and CEO, will appear in a virtual fireside chat on Thursday, April 23, 2026 at 3:00 PM ET as part of the Jones Trading Post-AACR Fireside Chat Series.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Whitehawk Therapeutics (Nasdaq: WHWK) said Dave Lennon, PhD, President and CEO, will appear in a virtual fireside chat on Thursday, April 23, 2026 at 3:00 PM ET as part of the Jones Trading Post-AACR Fireside Chat Series.
A live webcast is accessible via the company investor relations website and will be available for replay for approximately 30 days.
Details
News Market Reaction – WHWK
On Apr 17, the first trading day after this news, WHWK closed 2.84% below the previous close.
Data tracked by StockTitan Argus for the Apr 17 session.
Key Figures
- Fireside chat date
- April 23, 2026
- Jones Trading Post-AACR Fireside Chat Series
- Event time
- 3 PM ET
- Scheduled time of virtual fireside chat
- Replay window
- 30 days
- Webcast replay availability on IR website
Historical Context
-
Real-world data confirming MUC16 as a strong ADC target in gynecologic cancers.
-
Plans to present three ADC preclinical programs with encouraging efficacy and safety signals.
-
Year-end cash of $145.7M, ongoing Phase 1 recruitment and planned IND for HWK-206.
-
Participation in three early-March investor conferences with webcast access for investors.
-
Announcement of CEO presentation at Oppenheimer healthcare conference with webcast replay.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
antibody drug conjugate (adc) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISTOWN, N.J., April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the Jones Trading Post-AACR Fireside Chat Series on Thursday, April 23, 2026, at 3 PM ET.
A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact:
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-jones-trading-post-aacr-fireside-chat-series-302745213.html
SOURCE Whitehawk Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.